BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Beilman CL, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. Inflamm Bowel Dis 2016;22:870-9. [PMID: 26818419 DOI: 10.1097/MIB.0000000000000679] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease? Ann Gastroenterol 2018;31:413-24. [PMID: 29991886 DOI: 10.20524/aog.2018.0253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
2 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Reference Citation Analysis]
3 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
4 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
5 Borren NZ, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1234-9. [PMID: 28520589 DOI: 10.1097/MIB.0000000000001133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kwak MS, Cha JM, Ahn JH, Chae MK, Jeong S, Lee HH. Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study. Medicine (Baltimore) 2020;99:e18925. [PMID: 32150045 DOI: 10.1097/MD.0000000000018925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Saigusa N, Saigusa JI, Shinozaki M, Yokoyama T, Yokoi Y, Takami H, Miyahara R, Yokoyama Y. A series of seton techniques involving "top-down therapy" for patients with Crohn's disease who initially presented with perianal fistulas. J Anus Rectum Colon 2018;2:122-9. [PMID: 31559354 DOI: 10.23922/jarc.2017-044] [Reference Citation Analysis]
8 Papa A, Papa V, Lopetuso LR, Gasbarrini A, Tursi A. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therap Adv Gastroenterol 2020;13:1756284820968747. [PMID: 33149764 DOI: 10.1177/1756284820968747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Han M, Jung YS, Cheon JH, Park S. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study. Yonsei Med J 2020;61:382-90. [PMID: 32390361 DOI: 10.3349/ymj.2020.61.5.382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Simian D, Fluxá D, Flores L, Lubascher J, Ibáñez P, Figueroa C, Kronberg U, Acuña R, Moreno M, Quera R. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol 2016; 22(22): 5267-5275 [PMID: 27298570 DOI: 10.3748/wjg.v22.i22.5267] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
11 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study. Korean J Intern Med 2020;35:1104-13. [PMID: 32306709 DOI: 10.3904/kjim.2020.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Can J Gastroenterol Hepatol 2016;2016:2079582. [PMID: 27478817 DOI: 10.1155/2016/2079582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
14 Mastronardi M, Curlo M, Cavalcanti E, Burattini O, Cuppone R, Tauro R, De Santis S, Serino G, Pesole PL, Stasi E, Caruso ML, Donghia R, Guerra V, Giorgio P, Chieppa M. Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease. Front Med (Lausanne) 2019;6:234. [PMID: 31737635 DOI: 10.3389/fmed.2019.00234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. BMJ Open 2019;9:e024222. [PMID: 30782731 DOI: 10.1136/bmjopen-2018-024222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kotze PG, Magro DO, Saab B, Saab MP, Pinheiro LV, Olandoski M, Ayrizono MLS, Martinez CAR, Coy CSR. Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. Intest Res. 2018;16:62-68. [PMID: 29422799 DOI: 10.5217/ir.2018.16.1.62] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jung D, Lee S, Jeong I, Oh SH, Kim KM. Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2017;20:236-43. [PMID: 29302505 DOI: 10.5223/pghn.2017.20.4.236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
20 Aksentijevich I, Schnappauf O. Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases. Nat Rev Rheumatol 2021;17:405-25. [PMID: 34035534 DOI: 10.1038/s41584-021-00614-1] [Reference Citation Analysis]
21 Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Palacio FGM, de Souza LMP, Moreira JPL, Luiz RR, de Souza HSP, Zaltman C. Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis. BMC Gastroenterol 2021;21:192. [PMID: 33906627 DOI: 10.1186/s12876-021-01781-x] [Reference Citation Analysis]
23 Panchal H, Wagner M, Chatterji M, Taouli B, McBride R, Patterson JR, Ungaro R, Dubinsky M, Cho J, Sachar DB. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage. Dig Dis Sci 2019;64:3274-83. [PMID: 30607690 DOI: 10.1007/s10620-018-5434-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]